Treatment-Resistant Depression
Treatment-resistant Depression (TRD) typically refers to inadequate response to at least one antidepressant trial of adequate doses and duration. Treatment-resistant Depression is a relatively common occurrence in clinical practice, with up to 50–60% of the patients not achieving adequate response following antidepressant treatment.
Treatment-Resistant Depression Epidemiology Segmentation in the 7MM
- Total Diagnosed Prevalent Cases Treatment-Resistant Depression
- Age-Specific Cases of Treatment-Resistant Depression
- Gender-specific Cases of Treatment-Resistant Depression
Treatment-Resistant Depression Epidemiological Insights Observed in the 7MM (2021)
- The total prevalent cases of Treatment-Resistant Depression in the 7MM were estimated to be 5.8 million.
- The total prevalent cases of Treatment-Resistant Depression in the US were estimated to be 3.9 million.
- The total prevalent cases of Treatment-Resistant Depression in Germany was found to be 558k and in Italy, they were found to be 127k in the year 2021.
Treatment-Resistant Depression Market Insight
The market size of Treatment-Resistant Depression in the 7MM was found to be USD 2,450 million in 2021.
Treatment-Resistant Depression Emerging Therapies
The emerging drugs in the Treatment-Resistant Depression market are
- AXS-05
- VRAYLAR
- Esketamine DPI
- REL-1017
- COMP360
- MIJ821
- Liafensine
- MK-1942
- NV5138
- TS161
- AV-101, and many others
Treatment-Resistant Depression Key Players
The key players working in the Treatment-Resistant Depression market are
- Axsome Therapeutics
- AbbVie
- Celon Pharma
- Relmada Therapeutics
- COMPASS Pathways
- Novartis
- Denovo Biopharma
- Merck Sharp and Dohme Corp
- Navitor Pharmaceuticals, Inc.
- Supernus Pharmaceuticals, Inc.
- Taisho Pharmaceutical Co., Ltd
- VistaGen Therapeutics, and several others